生物皮肤替代品市场机会、成长动力、产业趋势分析及 2025-2034 年预测

2024 年全球生物皮肤替代品市场价值为 3.351 亿美元，预计 2025 年至 2034 年期间的复合年增长率为 8.5%。慢性伤口和烧伤的日益普遍推动了对先进伤口护理解决方案的需求，尤其是生物皮肤替代品。这些产品模仿天然皮肤，确保有效的组织整合和更快的癒合，使其成为全球医疗保健提供者的首选。随着糖尿病、肥胖症和老化相关疾病的负担不断增加，慢性伤口的发生率也在上升，为市场创造了巨大的成长机会。

人们对先进伤口护理治疗的认识不断提高，以及皮肤移植等传统方法的局限性，导致生物皮肤替代品的采用激增。微创手术和再生医学的进步进一步提高了这些产品的功效，使其成为现代医疗保健中不可或缺的一部分。随着生技公司大力投资研发，该产业正经历一波旨在改善患者治疗效果的创新解决方案浪潮。预计政府推动的改善伤口护理管理的倡议和大量新产品的批准将在预测期内维持市场发展势头。

市场根据产品类型分类，包括人类捐赠的无细胞动物衍生产品、组织衍生产品、组织工程皮肤和生物合成皮肤替代品。 2024年，人类捐赠组织衍生产品占65.8%的市占率。这些产品因其出色的复製人体皮肤和支持自然组织再生的能力而受到广泛青睐。临床试验和实际应用已证明其在治疗严重和慢性伤口方面的有效性，从而得到医疗保健专业人员的广泛采用。这些产品的不断改进，加上组织工程的进步，进一步巩固了它们的市场主导地位。

按应用细分，生物皮肤替代品用于急性伤口、慢性伤口和其他医疗需求。 2024 年，急性伤口领域占了 59.4% 的市场份额，这主要得益于对手术伤口和创伤相关损伤的快速有效治疗方案的需求。与传统的皮肤移植方法相比，人们对先进的生物皮肤替代品的偏好日益增长，这进一步推动了这一领域的扩张。这些产品提供快速、可靠的治疗解决方案，特别是在紧急情况下，立即护理对于预防併发症和感染至关重要。

2024 年美国生物皮肤替代品市场规模达 1.262 亿美元，未来成长前景广阔。糖尿病足溃疡、压疮和烧伤发病率的上升推动了对这些先进伤口护理解决方案的需求。此外，领先的生物技术公司的存在，加上 FDA 对创新皮肤替代品的批准不断增加，正在加速市场扩张。包括基于细胞和组织工程的产品在内的下一代生物皮肤替代品的推出正在重塑行业格局。随着技术的不断进步和再生医学投资的不断增加，美国市场有望持续成长，为製造商和医疗保健提供者提供光明的前景。

目录

第一章：方法论与范围

第二章：执行摘要

第三章：行业洞察

• 产业生态系统分析
• 产业衝击力
  • 成长动力
    • 慢性伤口的盛行率不断上升
    • 烧伤和创伤病例数不断增加
    • 伤口照护设施的普及率不断提高
    • 再生医学的技术进步
  • 产业陷阱与挑战
    • 与生物皮肤替代品相关的不良副作用
    • 缺乏报销政策
• 成长潜力分析
• 监管格局
• 未来市场趋势
• 差距分析
• 技术格局
• 波特的分析
• PESTEL分析

第四章：竞争格局

• 介绍
• 公司矩阵分析
• 公司市占率分析
• 竞争定位矩阵
• 供应商矩阵分析
• 策略仪表板

第五章：市场估计与预测：按类型，2021 年至 2034 年

• 主要趋势
• 人类捐赠组织衍生产品
• 无细胞动物源性产品
• 组织工程皮肤产品
• 生物合成皮肤产品

第六章：市场估计与预测：按应用，2021 年至 2034 年

• 主要趋势
• 急性伤口
• 慢性伤口
• 其他应用

第七章：市场估计与预测：依最终用途，2021 年至 2034 年

• 主要趋势
• 医院
• 门诊手术中心
• 专科诊所
• 其他最终用途

第八章：市场估计与预测：按地区，2021 年至 2034 年

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙
• 亚太地区
  • 日本
  • 中国
  • 印度
  • 韩国
  • 澳洲
• 拉丁美洲
  • 巴西
  • 阿根廷
  • 墨西哥
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋

第九章：公司简介

• Aroa Biosurgery
• Avita Medical
• BioTissue
• Integra LifeSciences
• MiMedx Group
• Misonix (Bioventus)
• Organogenesis
• ProgenaCare
• Smith & Nephew
• Stratatech Corporation (Mallinckrodt Pharmaceuticals)
• Stryker
• Tissue Regenix
• Vericel Corporation

The Global Biological Skin Substitutes Market was valued at USD 335.1 million in 2024 and is projected to expand at a CAGR of 8.5% from 2025 to 2034. The increasing prevalence of chronic wounds and burn injuries is driving demand for advanced wound care solutions, particularly biological skin substitutes. These products mimic natural skin, ensuring effective tissue integration and faster healing, making them a preferred choice for healthcare providers worldwide. As the burden of diabetes, obesity, and aging-related conditions continues to rise, so does the incidence of chronic wounds, creating significant growth opportunities for the market.

The increasing awareness regarding advanced wound care treatments and the limitations of conventional methods such as skin grafting have led to a surge in the adoption of biological skin substitutes. Minimally invasive procedures and regenerative medicine advancements have further enhanced the efficacy of these products, making them indispensable in modern healthcare. With biotechnology companies heavily investing in research and development, the industry is witnessing a wave of innovative solutions designed to improve patient outcomes. Government initiatives promoting better wound care management and a strong pipeline of new product approvals are expected to sustain market momentum over the forecast period.

The market is categorized based on product type, including human donor acellular animal-derived products, tissue-derived products, tissue-engineered skin, and biosynthetic skin substitutes. In 2024, human donor tissue-derived products accounted for 65.8% of the market share. These products are widely preferred due to their superior ability to replicate human skin and support natural tissue regeneration. Clinical trials and real-world applications have demonstrated their effectiveness in treating severe and chronic wounds, leading to their widespread adoption among healthcare professionals. The continuous refinement of these products, coupled with advancements in tissue engineering, is further reinforcing their market dominance.

Segmentation by application highlights that biological skin substitutes are used for acute wounds, chronic wounds, and other medical needs. The acute wounds segment held a 59.4% market share in 2024, primarily driven by the demand for rapid and effective treatment options in cases of surgical wounds and trauma-related injuries. The growing preference for advanced biological skin substitutes over traditional skin grafting methods is further fueling this segment's expansion. These products provide quick, reliable healing solutions, especially in emergency situations where immediate care is crucial for preventing complications and infections.

The U.S. Biological Skin Substitutes Market generated USD 126.2 million in 2024, with substantial growth prospects ahead. The rising incidence of diabetic foot ulcers, pressure ulcers, and burn injuries is propelling demand for these advanced wound care solutions. Additionally, the presence of leading biotechnology firms, coupled with increasing FDA approvals for innovative skin substitutes, is accelerating market expansion. The introduction of next-generation biological skin substitutes, including cell-based and tissue-engineered products, is reshaping the industry landscape. With continuous technological advancements and growing investments in regenerative medicine, the U.S. market is poised for sustained growth, offering promising opportunities for manufacturers and healthcare providers alike.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of chronic wounds
    • 3.2.1.2 Rising number of burn & trauma cases
    • 3.2.1.3 Growing adoption of wound care facilities
    • 3.2.1.4 Technological advancements in regenerative medicine
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Adverse side effects associated with biological skin substitutes
    • 3.2.2.2 Lack of reimbursement policies
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Future market trends
• 3.6 Gap analysis
• 3.7 Technology landscape
• 3.8 Porter's analysis
• 3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Company market share analysis
• 4.4 Competitive positioning matrix
• 4.5 Vendor matrix analysis
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Type, 2021 – 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Human donor tissue-derived products
• 5.3 Acellular animal-derived products
• 5.4 Tissue-engineered skin products
• 5.5 Biosynthetic skin products

Chapter 6 Market Estimates and Forecast, By Application, 2021 – 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Acute wounds
• 6.3 Chronic wounds
• 6.4 Other applications

Chapter 7 Market Estimates and Forecast, By End Use, 2021 – 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Hospitals
• 7.3 Ambulatory surgical centers
• 7.4 Specialty clinics
• 7.5 Other end use

Chapter 8 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 France
  • 8.3.3 UK
  • 8.3.4 Italy
  • 8.3.5 Spain
• 8.4 Asia Pacific
  • 8.4.1 Japan
  • 8.4.2 China
  • 8.4.3 India
  • 8.4.4 South Korea
  • 8.4.5 Australia
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Argentina
  • 8.5.3 Mexico
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE

Chapter 9 Company Profiles

• 9.1 Aroa Biosurgery
• 9.2 Avita Medical
• 9.3 BioTissue
• 9.4 Integra LifeSciences
• 9.5 MiMedx Group
• 9.6 Misonix (Bioventus)
• 9.7 Organogenesis
• 9.8 ProgenaCare
• 9.9 Smith & Nephew
• 9.10 Stratatech Corporation (Mallinckrodt Pharmaceuticals)
• 9.11 Stryker
• 9.12 Tissue Regenix
• 9.13 Vericel Corporation